

Massalia Therapeutics launches to advance novel therapies for patients with complex conditions intersecting oncology and fibrosis

Co-founded by Landmark BioVentures and researchers from Aix-Marseille University, Massalia will develop its sole-in-class therapeutic platform targeting conditions interlinking challenging diseases: fibrosis, neoplasm and neovascularization

Marseille, France, May 19, 2025 - Massalia Therapeutics, a biotechnology spin-off from the C2VN Institute (Cardiovascular and Nutrition Research Center), today announces its launch, with a mission to develop innovative therapeutics for patients living with fibrotic, neoplastic and neovascularized conditions. Built on its pioneering sole-in-class therapeutic platform, Massalia Therapeutics' innovative approach bridges the critical intersection of fibrosis, neoplasm and neovascularization, offering a new paradigm in addressing these complex and interlinked conditions.

Co-founded by Landmark BioVentures and researchers from Aix-Marseille University, with initial funding from multiple sources (financial terms not disclosed), Massalia Therapeutics leverages 20 years of research led by Dr. Marcel Blot-Chabaud and Pr. Nathalie Bardin's team at C2VN. Their groundbreaking discoveries have culminated in the identification and validation of the SANF (Soluble Angiogenic Neoplastic and Fibrotic) factor, a novel target with transformational potential as a therapeutic platform. The SANF factor has undergone extensive translational validation, demonstrating its critical role in driving pathological processes and resistance in cancer and fibrosis.

"We are excited to launch Massalia Therapeutics as the seventh company in Landmark BioVentures' growing nexus," said Zaki Sellam, executive chairman at Massalia, and CEO and co-founder of Landmark BioVentures. "The depth of biological and translational validation behind SANF is remarkable. Given its wide-ranging potential in oncology and fibrosis, we are confident that this therapeutic platform can redefine treatment paradigms in these challenging diseases."

Massalia Therapeutics is located at C2VN, the Faculty of Pharmacy of the Aix-Marseille University, a partner of La Timone University Hospital (Marseille, France), a renowned hub for biomedical innovation and research. The company is backed by a strong network of academic and strategic partners, including C2VN, Aix-Marseille University, Marseille University Hospitals and SATT Sud-Est (a regional economic development agency), whose contributions have been instrumental in the discovery and validation of SANF.

"The launch of Massalia Therapeutics represents a significant milestone in the translation of academic innovation into clinical solutions," said Françoise Dignat-George, director at C2VN. "We are excited to support this talented team as they work to bring their sole-in-class platform, targeting the SANF factor, to market, supporting patients in need."

Massalia Therapeutics is progressing towards clinical candidate nomination, with plans to enter into IND-enabling studies in the next 6-12 months.

About Landmark BioVentures

Landmark BioVentures is an integrative corporate and drug development company using resources smartly to advance multiple innovative therapies. Anchored by foundational science, LBV uncovers hidden gems with unrealized therapeutic potential by connecting non-obvious dots and taking a strategically-focused active hands-on approach with each nexus company. Led by a seasoned multidisciplinary team of drug developers, entrepreneurs and deal makers, LBV harnesses its specialized and industry-relevant drug development expertise and opportunistic and creative dealmaking in resource-constrained environments to streamline drug development, focusing on holistic value creation and capture.

www.landmarkbioventures.com or LinkedIn

About C2VN

C2VN, the only cardiovascular research unit in Marseille, is dedicated to improving the management of cardiovascular diseases, the leading cause of mortality and morbidity worldwide and the main complication of many chronic conditions. Cardiovascular diseases present a growing health and economic burden due to population aging and the rise of risk factors such as obesity and diabetes. C2VN focuses on four major research areas: nutrition and metabolism, cardiovascular pathophysiology, hemostasis and thrombosis, and cardiac adaptation and development. www.c2vn.univ-amu.fr or LinkedIn

About Massalia Therapeutics

Massalia Therapeutics is a preclinical-stage biotechnology company developing a sole-in-class therapeutic platform at the interface of fibrosis, neoplasm and neovascularization. Based on 20 years of cutting-edge and exclusive academic research and translational validation, the company is dedicated to advancing novel therapies for patients with complex and interconnected diseases. Co-created by Landmark BioVentures and SATT Sud-Est, Massalia Therapeutics is a spin-off from the C2VN Institute. The company's platform leverages this strong clinical background, combining deep insights into the molecular mechanisms driving fibrosis, neoplasm and neovascularization and the targeting of the SANF (Soluble Angiogenic Neoplastic and Fibrotic) factor. Massalia Therapeutics is poised to advance a pipeline of first-in-class therapies that address unmet medical needs in these challenging disease areas.

Media and analysts contact Andrew Lloyd & Associates Carol Leslie – Juliette Schmitt carol@ala.associates / juliette@ala.associates UK: +44 1273 952 481